Effects of Vitamin D3 on asymmetric- and symmetric dimethylarginine in arterial hypertension

Journal of Steroid Biochemistry and Molecular Biology

Volumn 175, Issue , 2018, Pages 157-163

  Grubler M R ^a,b   Gaksch, M ^a   Kienreich, K ^a   Verheyen, N D ^a   Schmid, J ^a   Mullner C ^a   Richtig, G ^a   Scharnagl, H ^a   Trummer, C ^a   Schwetz, V ^a   Meinitzer, A ^a   Pieske, B ^c   Marz W ^a,d   Tomaschitz, A ^a,e   Pilz, S ^a,f  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b BERN UNIVERSITY HOSPITAL   (Switzerland)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d SYNLAB ACADEMY   (Germany)

^e Bad Gleichenberg Clinic   (Austria)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Arterial hypertension; Cardiovascular disease; Endocrinology; Endothelial dysfunction; Vitamin D; Vitamin D deficiency

Indexed keywords

6 N,N' DIMETHYLARGININE; ANTIHYPERTENSIVE AGENT; ARGININE; COLECALCIFEROL; N(G),N(G) DIMETHYLARGININE; OLEOVIT D 3; 25-HYDROXYVITAMIN D; N,N-DIMETHYLARGININE; VITAMIN D;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; AGED; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; BLOOD; BLOOD PRESSURE; COMPLICATION; DIET THERAPY; DIETARY SUPPLEMENT; DRUG EFFECTS; MIDDLE AGED;

AGED; ANALYSIS OF VARIANCE; ARGININE; BLOOD PRESSURE; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 85008512180     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2016.12.014     Document Type: Article

References (54)

1. Holick, M.F., McCollum award lecture, 1994: vitamin D–new horizons for the 21 st century. Am. J. Clin. Nutr. 60 (1994), 619–630.
2. Holick, M.F., Binkley, N.C., Bischoff-Ferrari, H.A., Gordon, C.M., Hanley, D.A., Heaney, R.P., Murad, M.H., Weaver, C.M., Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J. Clin. Endocrinol. Metab. 97 (2012), 1153–1158, 10.1210/jc.2011-2601.
3. Holick, M.F., Vitamin D status: measurement, interpretation, and clinical application. Ann. Epidemiol. 19 (2009), 73–78, 10.1016/j.annepidem.2007.12.001.
4. Muscogiuri, G., Altieri, B., Annweiler, C., Balercia, G., Pal, H.B., Boucher, B.J., Cannell, J.J., Foresta, C., Grübler, M.R., Kotsa, K., Mascitelli, L., März, W., Orio, F., Pilz, S., Tirabassi, G., Colao, A., Vitamin D and chronic diseases: the current state of the art. Arch. Toxicol., 2016, 10.1007/s00204-016-1804-x.
5. Bouillon, R., Carmeliet, G., Verlinden, L., van Etten, E., Verstuyf, A., Luderer, H.F., Lieben, L., Mathieu, C., Demay, M., Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr. Rev. 29 (2008), 726–776, 10.1210/er.2008-0004.
6. Carlton-Conway, D., Tulloh, R., Wood, L., Kanabar, D., Vitamin D deficiency and cardiac failure in infancy. J. R. Soc. Med. 97 (2004), 238–239.
7. Kienreich, K., Tomaschitz, A., Verheyen, N., Pieber, T., Gaksch, M., Grübler, M.R., Pilz, S., Vitamin D and cardiovascular disease. Nutrients 5 (2013), 3005–3021, 10.3390/nu5083005.
8. Kienreich, K., Grubler, M., Tomaschitz, A., Schmid, J., Verheyen, N., Rutters, F., Dekker, J.M., Pilz, S., Vitamin D, arterial hypertension & cerebrovascular disease. Indian J. Med. Res. 137 (2013), 669–679.
9. Macdonald, H.M., Wood, A.D., Fraser, W.D., Simpson, W.G., Vitamin D status and ill health. Lancet Diabetes Endocrinol 2 (2016), e8–e9, 10.1016/s2213-8587(14)70047-6 (n.d).
10. Rosen, C.J., Adams, J.S., Bikle, D.D., Black, D.M., Demay, M.B., Manson, J.E., Murad, M.H., Kovacs, C.S., The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr. Rev. 33 (2012), 456–492, 10.1210/er.2012-1000.
11. Solak, Y., Covic, A., Kanbay, M., What do we know and do not know about vitamin D?: A causal association between Vitamin D receptor genetic polymorphism and hypertension. J. Clin. Hypertens 16 (2014), 627–628, 10.1111/jch.12383.
12. Pilz, S., Kienreich, K., Rutters, F., de Jongh, R., van Ballegooijen, A.J., Grübler, M., Tomaschitz, A., Dekker, J.M., Role of Vitamin D in the development of insulin resistance and type 2 diabetes. Curr. Diab. Rep. 13 (2012), 261–270, 10.1007/s11892-012-0358-4.
13. Lim, T., Flaxman, A.D., Danaei, G., Shibuya, K., Adair-Rohani, H., AlMazroa, M.A., Amann, M., Anderson, H.R., Andrews, K.G., Aryee, M., Atkinson, C., Bacchus, L.J., Bahalim, A.N., Balakrishnan, K., Balmes, J., Barker-Collo, S., Baxter, A., Bell, M.L., Blore, J.D., Blyth, F., Bonner, C., Borges, G., Bourne, R., Boussinesq, M., Brauer, M., Brooks, P., Bruce, N.G., Brunekreef, B., Bryan-Hancock, C., Bucello, C., Buchbinder, R., Bull, F., Burnett, R.T., Byers, T.E., Calabria, B., Carapetis, J., Carnahan, E., Chafe, Z., Charlson, F., Chen, H., Chen, J.S., Cheng, A.T.-A., Child, J.C., Cohen, K.E., Cowie, B.C., Darby, S., Darling, S., Davis, A., Degenhardt, L., Dentener, F., Des Jarlais, D.C., Devries, K., Dherani, M., Ding, E.L., Dorsey, E.R., Driscoll, T., Edmond, K., Ali, S.E., Engell, R.E., Erwin, P.J., Fahimi, S., Falder, G., Farzadfar, F., Ferrari, A., Finucane, M.M., Flaxman, S., Fowkes, F.G.R., Freedman, G., Freeman, M.K., Gakidou, E., Ghosh, S., Giovannucci, E., Gmel, G., Graham, K., Grainger, R., Grant, B., Gunnell, D., Gutierrez, H.R., Hall, W., Hoek, H.W., Hogan, A., Hosgood, H.D. III, Hoy, D., Hu, H., Hubbell, B.J., Hutchings, S.J., Ibeanusi, S.E., Jacklyn, G.L., Jasrasaria, R., Jonas, J.B., Kan, H., Kanis, J.A., Kassebaum, N., Kawakami, N., Khang, Y.-H., Khatibzadeh, S., Khoo, J.-P., Kok, C., Laden, F., Lalloo, R., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2010, 2224–2260, 10.1016/S0140-6736(12)61766-8.
14. Patel, B.M., Mehta, A.A., Aldosterone and angiotensin: role in diabetes and cardiovascular diseases. Eur. J. Pharmacol. 697 (2012), 1–12, 10.1016/j.ejphar.2012.09.034.
15. Calhoun, D.A., Aldosterone and cardiovascular disease smoke and fire. Circulation 114 (2006), 2572–2574, 10.1161/CIRCULATIONAHA.106.668715.
16. Funder, J.W., The nongenomic actions of aldosterone. Endocr. Rev. 26 (2005), 313–321, 10.1210/er.2005-0004.
17. Gekle, M., Grossmann, C., Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?. Pflüg. Arch. Eur. J. Physiol. 458 (2009), 231–246, 10.1007/s00424-008-0616-0.
18. Landim, M.B.P., Filho, A.C., Chagas, A.C.P., Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis. Clin. Sao Paulo Braz. 64 (2009), 471–478, 10.1590/S1807-59322009000500015.
19. Lüneburg, N., Xanthakis, V., Schwedhelm, E., Sullivan, L.M., Maas, R., Anderssohn, M., Riederer, U., Glazer, N.L., Vasan, R.S., Böger, R.H., Reference intervals for plasma L-arginine and the L-arginine:asymmetric dimethylarginine ratio in the Framingham Offspring Cohort. J. Nutr. 141 (2011), 2186–2190, 10.3945/jn.111.148197.
20. Vallance, P., Leone, A., Calver, A., Collier, J., Moncada, S., Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J. Cardiovasc. Pharmacol. 20:Suppl. 12 (1992), S60–S62.
21. Tousoulis, D., Georgakis, M., Oikonomou, E., Papageorgiou, N., Zaromitidou, M., Latsios, G., Papaioannou, S., Siasos, G., Asymmetric dimethylarginine: clinical significance and novel therapeutic approaches. Curr. Med. Chem. 22 (2015), 2871–2901, 10.2174/0929867322666150625095046.
22. Gkaliagkousi, E., Gavriilaki, E., Triantafyllou, A., Douma, S., Clinical significance of endothelial dysfunction in essential hypertension. Curr. Hypertens. Rep. 17 (2015), 1–9, 10.1007/s11906-015-0596-3.
23. Ngo, D.T., Sverdlov, A.L., McNeil, J.J., Horowitz, J.D., Does vitamin D modulate asymmetric dimethylarginine and C-reactive protein concentrations?. Am. J. Med. 123 (2010), 335–341, 10.1016/j.amjmed.2009.09.024.
24. Meric, C., Sonmez, A., Aydogdu, A., Tapan, S., Haymana, C., Basaran, Y., Baskoy, K., Sertoglu, E., Taslipinar, A., Bolu, E., Azal, O., Osteoprotegerin, fibroblast growth factor 23, and vitamin D3 levels in male patients with hypogonadism. Horm. Metab. Res. Horm. Stoffwechselforschung Horm. Métabolisme 46 (2014), 955–958, 10.1055/s-0034-1387789.
25. Okano, Y., Nagasaka, H., Optimal serum phenylalanine for adult patients with phenylketonuria. Mol. Genet. Metab. 110 (2013), 424–430, 10.1016/j.ymgme.2013.09.007.
26. Ngo, D.T.M., Chan, W.P., Rajendran, S., Heresztyn, T., Amarasekera, A., Sverdlov, A.L., O'Loughlin, P.D., Morris, H.A., Chirkov, Y.Y., Norman, R.J., Horowitz, J.D., Determinants of insulin responsiveness in young women: impact of polycystic ovarian syndrome, nitric oxide, and vitamin D. Nitric Oxide Biol. Chem. Off. J. Nitric Oxide Soc. 25 (2011), 326–330, 10.1016/j.niox.2011.06.005.
27. Bednarek-Skublewska, A., Smoleń, A., Jaroszyński, A., Załuska, W., Ksiazek, A., Effects of vitamin D3 on selected biochemical parameters of nutritional status inflammation, and cardiovascular disease in patients undergoing long-term hemodialysis. Pol. Arch. Med. Wewnętrznej 120 (2010), 167–174.
28. Sverdlov, A.L., Ngo, D.T.M., Chan, W.P.A., Chirkov, Y.Y., Horowitz, J.D., Aging of the nitric oxide system: are we as old as our NO?. J. Am. Heart Assoc., 3, 2014, e000973, 10.1161/JAHA.114.000973.
29. Syal, S.K., Kapoor, A., Bhatia, E., Sinha, A., Kumar, S., Tewari, S., Garg, N., Goel, P.K., Vitamin D deficiency, coronary artery disease, and endothelial dysfunction: observations from a coronary angiographic study in Indian patients. J. Invasive Cardiol. 24 (2012), 385–389.
30. Celik, M., Iyisoy, A., Celik, T., Yilmaz, M.I., Yuksel, U.C., Yaman, H., The relationship between L-arginine/ADMA ratio and coronary collateral development in patients with low glomerular filtration rate. Cardiol. J. 19 (2012), 29–35.
31. Böger, R.H., The pharmacodynamics of L-arginine. J. Nutr. 137 (2007), 1650S–1655S.
32. Bode-Böger, S.M., Scalera, F., Ignarro, L.J., The L-arginine paradox: importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol. Ther. 114 (2007), 295–306, 10.1016/j.pharmthera.2007.03.002.
33. Abu El Maaty, M.A., Hassanein, S.I., Hanafi, R.S., Gad, M.Z., Insights on vitamin D's role in cardiovascular disease: investigating the association of 25-hydroxyvitamin D with the dimethylated arginines. J. Nutr. Sci. Vitaminol. (Tokyo) 59 (2013), 172–177.
34. Kielstein, J.T., Salpeter, S.R., Bode-Boeger, S.M., Cooke, J.P., Fliser, D., Symmetric dimethylarginine (SDMA) as endogenous marker of renal function—a meta-analysis. Nephrol. Dial. Transplant. 21 (2006), 2446–2451, 10.1093/ndt/gfl292.
35. Pilz, S., Gaksch, M., Kienreich, K., Grübler, M., Verheyen, N., Fahrleitner-Pammer, A., Treiber, G., Drechsler, C., ó Hartaigh, B., Obermayer-Pietsch, B., Schwetz, V., Aberer, F., Mader, J., Scharnagl, H., Meinitzer, A., Lerchbaum, E., Dekker, J.M., Zittermann, A., März, W., Tomaschitz, A., Effects of Vitamin D on blood pressure and cardiovascular risk factors a randomized controlled trial. Hypertension 65 (2015), 1195–1201, 10.1161/HYPERTENSIONAHA.115.05319.
36. Grübler, M.R., Gaksch, M., Kienreich, K., Verheyen, N., Schmid, J., Hartaigh, B.Ó., Richtig, G., Scharnagl, H., Meinitzer, A., Fahrleitner-Pammer, A., März, W., Tomaschitz, A., Pilz, S., Effects of vitamin D supplementation on HbA1c and fasting glucose in hypertensive patients − a randomized controlled trial. Diabetes Obes. Metab., 2016, 10.1111/dom.12709.
37. Grübler, M.R., Gaksch, M., Kienreich, K., Verheyen, N., Schmid, J., Ó Hartaigh, B.W.J., Richtig, G., Scharnagl, H., Meinitzer, A., Pieske, B., Fahrleitner-Pammer, A., März, W., Tomaschitz, A., Pilz, S., Effects of Vitamin D supplementation on plasma aldosterone and renin-A randomized placebo-Controlled trial. J. Clin. Hypertens. Greenwich Conn. 18 (2016), 608–613, 10.1111/jch.12825.
38. Ernst, J.B., Tomaschitz, A., Grübler, M.R., Gaksch, M., Kienreich, K., Verheyen, N., März, W., Pilz, S., Zittermann, A., Vitamin D supplementation and hemoglobin levels in hypertensive patients: a randomized controlled trial. Int. J. Endocrinol, 2016, 2016, e6836402, 10.1155/2016/6836402.
39. Moher, D., Hopewell, S., Schulz, K.F., Montori, V., Gøtzsche, P.C., Devereaux, P.J., Elbourne, D., Egger, M., Altman, D.G., CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ, 340, 2010, c869, 10.1136/bmj.c869.
40. Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., Backer, G.D., Dominiczak, A., Galderisi, M., Grobbee, D.E., Jaarsma, T., Kirchhof, P., Kjeldsen, S.E., Laurent, S., Manolis, A.J., Nilsson, P.M., Ruilope, L.M., Schmieder, R.E., Sirnes, P.A., Sleight, P., Viigimaa, M., Waeber, B., Zannad, F., Redon, J., Dominiczak, A., Narkiewicz, K., Nilsson, P.M., Burnier, M., Viigimaa, M., Ambrosioni, E., Caufield, M., Coca, A., Olsen, M.H., Schmieder, R.E., Tsioufis, C., van de Borne, P., Zamorano, J.L., Achenbach, S., Baumgartner, H., Bax, J.J., Bueno, H., Dean, V., Deaton, C., Erol, C., Fagard, R., Ferrari, R., Hasdai, D., Hoes, A.W., Kirchhof, P., Knuuti, J., Kolh, P., Lancellotti, P., Linhart, A., Nihoyannopoulos, P., Piepoli, M.F., Ponikowski, P., Sirnes, P.A., Tamargo, J.L., Tendera, M., Torbicki, A., Wijns, W., Windecker, S., Clement, D.L., Coca, A., Gillebert, T.C., Tendera, M., Rosei, E.A., Ambrosioni, E., Anker, S.D., Bauersachs, J., Hitij, J.B., Caulfield, M., Buyzere, M.D., Geest, S.D., Derumeaux, G.A., Erdine, S., Farsang, C., Funck-Brentano, C., Gerc, V., Germano, G., Gielen, S., Haller, H., Hoes, A.W., Jordan, J., Kahan, T., Komajda, M., Lovic, D., Mahrholdt, H., Olsen, M.H., Ostergren, J., Parati, G., Perk, J., Polonia, J., Popescu, B.A., Reiner, Ž., Rydén, L., Sirenko, Y., Stanton, A., Struijker-Boudier, H., Tsioufis, C., van de Borne, P., Vlachopoulos, C., Volpe, M., Wood, D.A., ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 34 (2013), 2159–2219, 10.1093/eurheartj/eht151.
41. Meinitzer, A., Puchinger, M., Winklhofer-Roob, B.M., Rock, E., Ribalta, J., Roob, J.M., Sundl, I., Halwachs-Baumann, G., März, W., Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method. Clin. Chim. Acta Int. J. Clin. Chem. 384 (2007), 141–148, 10.1016/j.cca.2007.07.006.
42. Schmid, J., Kienreich, K., Gaksch, M., Grübler, M., Raggam, R., Meinitzer, A., Rutters, F., Dekker, J.M., März, W., Verheyen, N., The importance of assays in vitamin D status classification: a comparison of four automated 25-hydroxyvitamin D immunoassays. LaboratoriumsMedizin 37 (2013), 261–268.
43. Roth, M., Fluorescence reaction for amino acids. Anal. Chem. 43 (1971), 880–882, 10.1021/ac60302a020.
44. Schwarz, E.L., Roberts, W.L., Pasquali, M., Analysis of plasma amino acids by HPLC with photodiode array and fluorescence detection. Clin. Chim. Acta Int. J. Clin. Chem. 354 (2005), 83–90, 10.1016/j.cccn.2004.11.016.
45. Grübler, M.R., Kienreich, K., Gaksch, M., Verheyen, N., Fahrleitner-Pammer, A., Schmid, J., Grogorenz, J., Ablasser, K., Pieske, B., Tomaschitz, A., Pilz, S., Aldosterone to active renin ratio is associated with nocturnal blood pressure in obese and treated hypertensive patients: the styrian hypertension study. J. Clin. Hypertens. 16 (2014), 289–294, 10.1111/jch.12274.
46. Hartaigh, B.ó., Gaksch, M., Kienreich, K., Grübler, M.R., Verheyen, N., März, W., Tomaschitz, A., Gill, T.M., Pilz, S., Associations of daytime, nighttime, and 24-Hour heart rate with four distinct markers of inflammation in hypertensive patients: the styrian hypertension study. J. Clin. Hypertens. 16 (2014), 856–861, 10.1111/jch.12420.
47. Grübler, M.R., Kienreich, K., Gaksch, M., Verheyen, N., Hartaigh, B.Ó., Fahrleitner-Pammer, A., März, W., Schmid, J., Oberreither, E.-M., Wetzel, J., Catena, C., Sechi, L.A., Pieske, B., Tomaschitz, A., Pilz, S., Aldosterone-to-Renin ratio is associated with reduced 24-Hour heart rate variability and QTc prolongation in hypertensive patients. Medicine (Baltimore), 95, 2016, e2794, 10.1097/MD.0000000000002794.
48. White, I.R., Horton, N.J., Carpenter, J., Pocock, S.J., Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ, 342, 2011, d40.
49. Wang, R., Lagakos, S.W., Ware, J.H., Hunter, D.J., Drazen, J.M., Statistics in medicine — reporting of subgroup analyses in clinical trials. N. Engl. J. Med. 357 (2007), 2189–2194, 10.1056/NEJMsr077003.
50. Cashman, K.D., Dowling, K.G., Škrabáková, Z., Gonzalez-Gross, M., Valtueña, J., De Henauw, S., Moreno, L., Damsgaard, C.T., Michaelsen, K.F., Mølgaard, C., Jorde, R., Grimnes, G., Moschonis, G., Mavrogianni, C., Manios, Y., Thamm, M., Mensink, G.B., Rabenberg, M., Busch, M.A., Cox, L., Meadows, S., Goldberg, G., Prentice, A., Dekker, J.M., Nijpels, G., Pilz, S., Swart, K.M., van Schoor, N.M., Lips, P., Eiriksdottir, G., Gudnason, V., Cotch, M.F., Koskinen, S., Lamberg-Allardt, C., Durazo-Arvizu, R.A., Sempos, C.T., Kiely, M., Vitamin D deficiency in europe: pandemic?. Am. J. Clin. Nutr 103 (2016), 1033–1044, 10.3945/ajcn.115.120873.
51. Mosekilde, L., Vestergaard, P., Rejnmark, L., The pathogenesis, treatment and prevention of osteoporosis in men. Drugs 73 (2012), 15–29, 10.1007/s40265-012-0003-1.
52. Pilz, S., Verheyen, N., Grübler, M.R., Tomaschitz, A., März, W., Vitamin D and cardiovascular disease prevention. Nat. Rev. Cardiol. 13 (2016), 404–417, 10.1038/nrcardio.2016.73.
53. Brennan, P., Croft, P., Interpreting the results of observational research: chance is not such a fine thing. BMJ 309 (1994), 727–730, 10.1136/bmj.309.6956.727.
54. Amarasekera, A.T., Sverdlov, A.L., Roberts, M.S., Horowitz, J.D., Ngo, D.T., Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations; independent of vitamin D status. Eur. Heart J., 34, 2013, P613, 10.1093/eurheartj/eht307.P613.